A proteomics study reported that the EA therapy could reduce oocyte numbers and preserve the vascular barrier against OHSS by triggering a CD200-mediated anti-inflammatory response, and could reverse the down-regulation of CD200 in the ovaries of the OHSS rat model [135]. Here, CD200 is linked to ovarian hyperstimulation syndrome.